3 rows
84 mg via Other (multi-dose)
Reported in 3 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Other
Esketamine clinical studies for Depressive Disorders include 24 structured dose rows across 20 linked trials. Common source-reported dose patterns include 84 mg, 0.2 mg/kg, 56 mg. Interpret these as descriptive trial protocols, not treatment recommendations.
This page summarizes source-structured dosing used in linked human clinical studies. It preserves the source-reported unit, route, frequency, and regimen notes where available.
Patterns group structured dose rows with the same reported dose, route, and regimen type. They preserve source units and do not imply clinical equivalence.
Reported in 3 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Other
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Other
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Other
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: IV
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Intranasal
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Each row comes from a linked clinical trial intervention. Rows with missing or reviewed-incomplete dosing stay visible instead of being filled by inference.
| Study | Arm | Dose | Route and regimen | Source status |
|---|---|---|---|---|
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD) | Esketamine Esketamine | 56-84 mg | Other | flexible twice-weekly (Day1–Week4), then weekly (Week5–8), then weekly or every 2 weeks (Week9–32) Nasal spray; doses 28, 56, or 84 mg; 28 mg initial option for elderly/Japanese ancestry; flexible uptitration per protocol. | Not reviewed existing-data | esketamine-nasal-spray-versus-quetiapine-for-treatment-resistant-depression |
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment | Esketamine Esketamine | Not reported | Other weekly or every 2 weeks Self-administered intranasal esketamine per prior study dosing and investigator judgment; dosing adjusted per local SmPC. | Not reviewed long-term-treatment-with-esketamine-nasal-spray-in-patients-with-treatment-resistant-depression |
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3) | Esketamine Nasal Spray Esketamine | 28-84 mg | Inhalation | flexible twice per week (induction) then weekly or every other week (maintenance) Flexible dosing: 28, 56 or 84 mg depending on age and prior study dosing; participants <65 typically 56 or 84 mg, ≥65 start at 28 mg. Induction = twice weekly for 4 weeks (≈8 sessions); maintenance individualised after Week 4. Dose data found during issue #220 source review. | Source Backed registry | registry:NCT02782104 Depression (SUSTAIN-3) NCT02782104 https://clinicaltrials.gov/study/NCT02782104 Open-label, long-term extension Phase III safety study (n≈1148) of esketamine nasal spray (flexible 28–84 mg dosing) in participants with treatment-resistant depression, induction twice weekly for 4 weeks then individualised maintenance. This open-label extension evaluates the long-term |
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2) | Esketamine + antidepressant Esketamine | 56-84 mg | Intranasal twice weekly (induction); then weekly or every other week (maintenance) Flexible dosing: <65 yrs 56 or 84 mg; ≥65 yrs start 28 mg (28, 56 or 84 mg possible). | Not reviewed existing-data | adverse-events-and-measurement-of-dissociation-after-the-first-dose-of-esketamin |
A randomised controlled trial of oral S-ketamine as add-on medication for patients with treatment-resistant major depressive disorder | S-ketamine Esketamine | Needs review | Oral | multi-dose three times daily Oral S‑ketamine TID for 6 weeks with tapered start and finish; exact mg not specified in registry. paper:oral-esketamine-in-patients-with-treatment-resistant-depression-a-double-blind-r: Multiple candidate dose values found near Esketamine (30 mg, 0.5-3 mg/kg); manual mapping needed. | Supplement is not parsed as PDF: paper:oral-esket... | Needs Review needs-review | oral-esketamine-in-patients-with-treatment-resistant-depression-a-double-blind-r |
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression | Esketamine 56 mg Esketamine | 56 mg | Other twice a week | 8 doses Intranasal self-administration; JNJ-54135419 | Not reviewed existing-data | esketamine-monotherapy-in-adults-with-treatment-resistant-depression-a-randomize |
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression | Esketamine 84 mg Esketamine | 84 mg | Other twice a week | 8 doses Intranasal self-administration; JNJ-54135419 | Not reviewed existing-data | esketamine-monotherapy-in-adults-with-treatment-resistant-depression-a-randomize |
A Study to Evaluate the Efficacy and Safety of Esketamine Combined With Oral Antidepressants in the Treatment of Major Depressive Disorder With Suicidal Ideation | Intravenous esketamine Esketamine | 0.25 mg/kg | IV | multi-dose 3 infusions over 5 days (days 1, 3, and 5) | 3 doses Infused in 50 mL of 0.9% saline over 40 minutes. | Not reviewed existing-data | short-term-cognitive-effects-of-repeated-dose-esketamine-in-adolescents-with-maj |
A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I) | Esketamine + SOC Esketamine | 84 mg | Other | multi-dose twice weekly | 8 doses Days 1,4,8,11,15,18,22,25 (8 doses over 4 weeks). | Not reviewed existing-data | esketamine-nasal-spray-for-rapid-reduction-of-major-depressive-disorder-symptoms |
A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE II) | Esketamine + Standard of care Esketamine | 84 mg | Other | multi-dose two times per week | 8 doses Intranasal administration on Days 1, 4, 8, 11, 15, 18, 22, and 25. | Not reviewed existing-data | esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients-wi |
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | Esketamine + AD Esketamine | 56-84 mg | Other | multi-dose twice per week | 8 doses Intranasal spray; start 56 mg on Day 1; may be increased to 84 mg per investigator discretion. | Not reviewed existing-data | efficacy-and-safety-of-flexibly-dosed-esketamine-nasal-spray-plus-a-newly-initia |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1) | Esketamine 56 mg Esketamine | 56 mg | Other twice per week | 8 doses Fixed 56 mg dosing twice weekly. | Not reviewed existing-data | treatment-response-with-esketamine-nasal-spray-plus-an-oral-antidepressant-in-pa |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1) | Esketamine 84 mg Esketamine | 84 mg | Other twice per week | 8 doses Day 1 56 mg then 84 mg from Day 4 onwards per protocol titration. | Not reviewed existing-data | treatment-response-with-esketamine-nasal-spray-plus-an-oral-antidepressant-in-pa |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-2) | Esketamine + oral antidepressant Esketamine | 56-84 mg | Other twice per week | 8 doses Intranasal; start 56 mg Day 1; may increase to 84 mg on Day 4 and on Days 8/11; dose may be reduced for tolerability; stable after Day 15. | Not reviewed existing-data | treatment-response-with-esketamine-nasal-spray-plus-an-oral-antidepressant-in-pa |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3) | Esketamine + AD Esketamine | 28-84 mg | Intranasal twice per week | 8 doses Day 1 = 28 mg; Day 4 = 28 or 56 mg; subsequent doses 28, 56 or 84 mg per investigator titration based on efficacy/tolerability. | Not reviewed existing-data | efficacy-and-safety-of-esketamine-nasal-spray-by-sex-in-patients-with-treatment- |
Clinical Study of Esketamine for Improving Depressive Symptoms in Patients With Lung Cancer After Smoking Cessation | Esketamine Esketamine | 0.5 mg/kg | Intranasal | multi-dose weekly | 8 doses Administered once a week for 8 sessions | Not reviewed existing-data | efficacy-and-safety-of-esketamine-for-smoking-cessation-among-patients-diagnosed |
Effect of a single low-dose dose of esketamine on postpartum depression and quality of recovery in women undergoing cesarean section: a prospective, randomised controlled study | Esketamine group Esketamine | 0.2 mg/kg | IV | fixed single dose | 1 dose Infused over 40 minutes immediately after fetal delivery and umbilical cord ligation; combined with PCIA for pain relief maintenance. | Not reviewed existing-data | single-low-dose-esketamine-improves-postpartum-depression-symptoms-and-recovery-quality-in |
ESKALE: descriptive study of patients with treatment-resistant depression treated with esketamine, within the framework of the cohort ATU, the post-ATU program or the post-marketing period | Esketamine Esketamine | Not reported | intranasal null Used in a real-world, non-interventional study (ESKALE) for patients with treatment-resistant depression. | Not reviewed effectiveness-and-factors-associated-with-esketamine-response-during-the-4-week-induction-period |
Esketamine vs Midazolam for MDD with Fluctuating Antidepressant Response: A Double-Blind Pilot RCT (Xiao 2023, Beijing Anding Hospital) | Esketamine-treated group Esketamine | 0.2 mg/kg | IV | fixed single dose | 1 dose Administered over 40 minutes via syringe pump; participants maintained ongoing adequate antidepressant treatment (ADT). | Not reviewed existing-data | esketamine-vs-midazolam-in-boosting-the-efficacy-of-oral-antidepressants-for-maj |
Oral Esketamine for Severe TRD: Multicenter Compassionate Use Open-Label Study (Veraart 2025, Netherlands) | Oral esketamine Esketamine | 0.5 mg/kg | Oral | titrated twice weekly | 12 doses Doses were individually titrated from 0.5 or 1 mg/kg up to a maximum of 2.0 mg/kg (June 2017–April 2019) or 3.0 mg/kg (May 2019–June 2023). | Not reviewed existing-data | oral-esketamine-for-patients-with-severe-treatment-resistant-depression-effectiv |
Racemic Ketamine vs S(+)-Esketamine for TRD: Bicentric Double-Blind RCT (UFBA Brazil, UMIN000032355) | Esketamine Esketamine | 0.25 mg/kg | IV | fixed single dose | 1 dose Infusion duration of 40 min | Not reviewed existing-data | neurocognitive-aspects-of-ketamine-and-esketamine-on-subjects-with-treatment-res |
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide | Esketamine 28 mg Esketamine | 28 mg | Other | multi-dose three doses 28 mg delivered as 2 x 14 mg sprays. | Not reviewed existing-data | effect-of-esketamine-on-depressive-symptoms-in-adolescents-with-major-depressive |
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide | Esketamine 56 mg Esketamine | 56 mg | Other | multi-dose three doses 56 mg delivered as 4 x 14 mg sprays. | Not reviewed existing-data | effect-of-esketamine-on-depressive-symptoms-in-adolescents-with-major-depressive |
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide | Esketamine 84 mg Esketamine | 84 mg | Other | multi-dose three doses 84 mg delivered as 6 x 14 mg sprays (3 per nostril) as described. | Not reviewed existing-data | effect-of-esketamine-on-depressive-symptoms-in-adolescents-with-major-depressive |